Totipotent Stem Cells represent the most potent and versatile type of stem cell, possessing the unique ability to differentiate into any cell type in the human body, as well as supporting the development of both embryonic and extraembryonic tissues. Totipotent cells can give rise to every cell type required for embryonic development, making them distinct from pluripotent cells, which can differentiate into any cell type but not support the formation of extraembryonic tissues like the placenta. The earliest stages of embryonic development involve totipotent cells, and they are capable of forming an entire organism. Following fertilization, the zygote is totipotent, and as cell division progresses, totipotency is retained in the cells of the morula. However, as the blastocyst forms, cells become pluripotent, with the ability to differentiate into the three germ layers—ectoderm, mesoderm, and endoderm. While totipotent cells are crucial for embryonic development, they are not utilized in most regenerative medicine applications due to ethical and practical considerations, particularly related to the use of embryos. Instead, pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, are more commonly employed for their versatility and ethical feasibility in various research and therapeutic contexts.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy